Medicamen Biotech Limited has informed the Exchange about change in Management
MEDICAMEQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medicamen Biotech has announced board changes effective August 12, 2025. The company is appointing two new Independent Directors — Mr. Sham Goel (a Chartered Accountant with 30+ years in finance and taxation) for 5 years, and Mr. Shaival Saurabh (30+ years experience in branding and advertising) for 3 years. This is a planned succession because the existing Independent Directors, Mr. Harish Pande and Mr. Arun Kumar, are completing their maximum permitted tenure of two consecutive 5-year terms, expiring February 26, 2026. Additionally, Mr. Ashwani Kumar Sharma has been redesignated from Non-Executive Director to Whole Time Director (Executive Director) for a 5-year term. All appointments are subject to shareholder approval at the upcoming AGM.
This is a routine, regulator-driven board refresh and does not signal any operational or financial concern. Shareholders can expect continuity in governance, with the board gaining fresh expertise in finance/taxation and branding. The designation change strengthens the executive leadership by adding a Whole Time Director. Overall, neutral to mildly positive for governance quality.